NEUP
NASDAQ · Biotechnology
Neuphoria Therapeutics Inc
$4.45
+0.05 (+1.14%)
Open$4.49
Previous Close$4.40
Day High$4.50
Day Low$4.36
52W High$21.40
52W Low$3.65
Volume—
Avg Volume62.9K
Market Cap24.70M
P/E Ratio—
EPS$-8.77
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+232.4% upside
Current
$4.45
$4.45
Target
$14.79
$14.79
$9.77
$14.79 avg
$16.23
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 52.11M | 5.17M | 4.87M |
| Net Income | -1,232,237 | -354,866 | -256,361 |
| Profit Margin | -2.4% | -6.9% | -5.3% |
| EBITDA | -1,552,186 | -507,265 | -425,609 |
| Free Cash Flow | — | -183,163 | -132,058 |
| Rev Growth | +696.2% | -7.1% | +6.1% |
| Debt/Equity | 0.00 | 0.39 | 0.29 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $251.53 | -1.09% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $361.16 | +0.17% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.13 | -0.16% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $494.74 | -0.98% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $628.06 | -0.59% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $297.43 | +1.33% | 69.3 | 39.97B |